Treatment of Lichen Planopilaris With Abrocitinib

This case study reports the first instance of complete remission of Lichen Planopilaris (LPP) in a 58-year-old woman following treatment with abrocitinib, a selective JAK-1 inhibitor. The patient, who had a history of allergic asthma, rhinitis, and atopic dermatitis, showed significant improvement in LPP symptoms after switching from tralokinumab to abrocitinib, alongside topical clobetasol propionate and minoxidil. At the 3-month follow-up, the patient experienced no scalp pruritus or burning, and her LPP Activity Index (LPPAI) score dropped to 0, indicating remission. The study suggests that abrocitinib could be a promising treatment for LPP, although further research is needed to fully understand the therapeutic potential of JAK inhibitors in managing LPP and similar inflammatory conditions. No adverse events were reported during the treatment period.